Auro Laboratories Limited Reports ₹1.05 Crore Q1 FY27 Profit

Auro Laboratories Limited reported standalone net profit of ₹1.05 crore for the quarter ended June 2026, compared with a net loss of ₹0.11 crore a year earlier, while sales rose 216.61% to ₹8.77 crore from ₹2.77 crore.

What did Auro Laboratories report for Q1 FY27?

Auro Laboratories reported a return to profit in Q1 FY27, with standalone net profit of ₹1.05 crore for the June 2026 quarter. The company had recorded a standalone net loss of ₹0.11 crore in the quarter ended June 2025. The result was approved by the board on 14 August 2026 as part of the unaudited Q1 FY2027 financial results.

Sales were ₹8.77 crore in the June 2026 quarter, against ₹2.77 crore in June 2025. This represented year-on-year growth of 216.61%. The supplied results summary also describes Q1 FY27 revenue as ₹8 crore and net profit as ₹1 crore, which are rounded figures; the company update provides the more precise standalone sales and profit numbers.

How does the June 2026 performance compare with the prior year?

Auro Laboratories' June 2026 sales were more than three times the level reported in the corresponding June 2025 quarter. The increase from ₹2.77 crore to ₹8.77 crore was accompanied by a move from loss to profit, providing the central financial change in the Q1 FY27 release.

The comparison is based on standalone figures. Auro Laboratories manufactures and sells active pharmaceutical ingredients, intermediates and generic formulations in India and international markets. Its quarterly performance can therefore be influenced by the timing and scale of product sales, but the supplied information does not provide a product-wise or geography-wise revenue break-up for Q1 FY27.

The reported profit of ₹1.05 crore is modest in absolute terms, but it contrasts with the ₹0.11 crore loss in the comparable prior-year quarter. No operating margin, tax expense or earnings-per-share figure for the June 2026 standalone quarter has been provided in the source material.

What do earlier quarterly figures show about Auro Laboratories' performance?

Earlier reported figures show significant variation across quarters, including a recovery in the September 2025 consolidated results. For the September 2025 quarter, consolidated sales stood at ₹8.84 crore, operating profit was ₹2.35 crore and net profit was ₹0.72 crore. Operating profit margin was 26.58%, compared with 1.08% in the June 2025 quarter.

In June 2025, consolidated sales were ₹2.77 crore, operating profit was ₹0.03 crore and net loss was ₹0.11 crore. In September 2024, consolidated sales were ₹3.10 crore and net profit was ₹0.36 crore. The September 2025 result also included profit before tax of ₹1.72 crore, a tax rate of 58.14%, and earnings per share of ₹1.16.

The June 2026 release is identified as standalone, while the earlier September 2025 and June 2025 figures in the supplied table are consolidated. Investors should therefore avoid treating all of these numbers as a like-for-like trend without checking the reported basis and accompanying financial statements.

When will Auro Laboratories release its Q2 FY27 results?

Auro Laboratories has scheduled a board meeting for 13 November 2026 to consider and approve unaudited financial results for the quarter and half year ended 30 September 2026. The agenda also includes the limited review report for those financial statements.

The company had stated that its trading window would remain closed until 48 hours after the board meeting. The supplied information describes the meeting as scheduled and does not provide the Q2 FY27 financial outcome. As a result, no conclusion can be drawn from the available information on September-quarter sales, margins, profit or cash position.

The Q2 announcement is relevant because it will provide the next disclosed financial update following the June-quarter turnaround. It will also cover the first half ended September 2026, giving a broader reported view of the company's financial performance during FY27.

What does the result mean for investors?

For investors, the key reported development is the combination of higher sales and a return to standalone profitability in Q1 FY27. Sales increased by ₹6.00 crore year-on-year, while the company moved from a ₹0.11 crore loss to a ₹1.05 crore profit. These are reported financial outcomes rather than projections for subsequent quarters.

The available figures also highlight why comparability matters. The historical quarterly table is consolidated, while the latest June 2026 update is standalone. In addition, no share-price movement, valuation measure, order book, product contribution or management guidance has been provided. The scheduled September-quarter results will be the next official financial data point in the supplied record.

Conclusion

Auro Laboratories' Q1 FY27 update showed a standalone profit turnaround, with net profit of ₹1.05 crore and sales of ₹8.77 crore. The year-on-year comparison indicates a substantial increase in sales from the June 2025 quarter, when the company recorded a loss, while earlier consolidated results show that quarterly operating performance has varied materially.

Investors will next watch the board meeting scheduled for 13 November 2026, when Auro Laboratories is due to consider Q2 FY27 and first-half FY27 unaudited results for the period ended 30 September 2026. The source does not disclose those results in advance, so reported sales, profitability and the limited review outcome remain pending.